Canada markets close in 4 hours 59 minutes

Amgen Inc. (AMGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
229.20+3.80 (+1.69%)
As of 11:01AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close225.40
Bid229.25 x 800
Ask229.57 x 800
Day's Range226.42 - 229.85
52 Week Range198.64 - 258.45
Avg. Volume2,614,185
Market Cap122.606B
Beta (5Y Monthly)0.56
PE Ratio (TTM)19.49
EPS (TTM)11.76
Earnings DateOct 31, 2022 - Nov 04, 2022
Forward Dividend & Yield7.76 (3.44%)
Ex-Dividend DateAug 17, 2022
1y Target Est253.12
  • Motley Fool

    Could This Biosimilar Drug Candidate Be a Hit for Novartis?

    On Sept. 19, Novartis (NYSE: NVS) shared positive news with investors regarding the clinical trial results for its biosimilar drug candidate to Amgen's (NASDAQ: AMGN) osteoporosis medicine Prolia. With Prolia set to lose exclusivity in the U.S. in 2025, Novartis could be close to booking some revenue from its biosimilar drug. Let's go over the outcome of the clinical trial and the U.S. osteoporosis market to figure this out.

  • Simply Wall St.

    Amgen Inc. (NASDAQ:AMGN) Looks Just Right

    With a price-to-earnings (or "P/E") ratio of 18.3x Amgen Inc. ( NASDAQ:AMGN ) may be sending bearish signals at the...

  • Motley Fool

    3 Biotech Stocks to Buy and Hold for the Next 10 Years

    Several biotech stocks have outperformed the struggling market this year. This list includes Vertex Pharmaceuticals (NASDAQ: VRTX), Exelixis (NASDAQ: EXEL), and Amgen (NASDAQ: AMGN). Let's consider why these three biotechs are solid buys for the next decade.